Pasar al contenido principal

MODULACION DE LAS FUNCIONES COGNITIVAS POR RECEPTORES CANNABINOIDES PERIFERICOS: RELEVANCIA EN LA DISCAPACIDAD INTELECTUAL Y MECANISMOS INVOLUCRADOS

RTI2018-099282-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome

  • Navarro Romero, Alba, 1990-
  • Galera López, Lorena, 1993-
  • Ortiz Romero, Paula, 1994-
  • Llorente-Ovejero, Alberto
  • Los Reyes-Ramírez, Lucía de
  • Bengoetxea de Tena, Iker
  • Garcia-Elias Heras, Anna
  • Mas Stachurska, Aleksandra
  • Reixachs i Solé, Marina
  • Pastor, Antonio
  • Torre Fornell, Rafael de la
  • Maldonado, Rafael, 1961-
  • Benito Villabriga, Begoña
  • Eyras Jiménez, Eduardo
  • Rodríguez-Puertas, Rafael
  • Campuzano Uceda, María Victoria
  • Ozaita Mintegui, Andrés, 1969-
Williams-Beuren syndrome (WBS) is a rare genetic multisystemic disorder characterized by mild-to-moderate intellectual disability and hypersocial phenotype, while the most life-threatening features are cardiovascular abnormalities. Nowadays, there are no pharmacological treatments to directly ameliorate the main traits of WBS. The endocannabinoid system (ECS), given its relevance for both cognitive and cardiovascular function, could be a potential druggable target in this syndrome. We analyzed the components of the ECS in the complete deletion (CD) mouse model of WBS and assessed the impact of its pharmacological modulation in key phenotypes relevant for WBS. CD mice showed the characteristic hypersociable phenotype with no preference for social novelty and poor short-term object-recognition performance. Brain cannabinoid type-1 receptor (CB1R) in CD male mice showed alterations in density and coupling with no detectable change in main endocannabinoids. Endocannabinoid signaling modulation with subchronic (10 days) JZL184, a selective inhibitor of monoacylglycerol lipase, specifically normalized the social and cognitive phenotype of CD mice. Notably, JZL184 treatment improved cardiovascular function and restored gene expression patterns in cardiac tissue. These results reveal the modulation of the ECS as a promising novel therapeutic approach to improve key phenotypic alterations in WBS., This study was supported by Ministerio de Economía, Innovación y Competitividad (MINECO), Spain #RTI2018-099282-B-I00B to A.O., #SAF2017-84060-R to R.M.; Generalitat de Catalunya, Spain (2017SGR-669 to R.M.); Ministerio de Ciencia e Innovación (SAF2016-78508-R; AEI/MINEICO/FEDER, UE) to VC. Basque Government IT1454-22 to the 'Neurochemistry and Neurodegeneration' consolidated research group to R R-P. Instituto de Salud Carlos III (PI20/00153, co-funded by the European Union [ERDF 'A way to make Europe']) to R R-P. ICREA (Institució Catalana de Recerca i Estudis Avançats, Spain) Academia to A.O. and R.M. Grant 'Unidad de Excelencia María de Maeztu', funded by the MINECO (#MDM-2014-0370); IPEP MdM 2017 to A.O. and E.E. FEDER, European Commission funding is also acknowledged.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes

  • Vázquez-Oliver, Anna
  • Pérez-García, Silvia
  • Romero-Pérez, Rafael
  • Pizarro Lozano, Ma. Nieves
  • Galarraga-Shinin, Diana
  • Molina-Porcel, Laura
  • Torre Fornell, Rafael de la
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
INTRODUCTION: Down syndrome (DS) is the most common genetic cause of intellectual disability, affecting cognitive function and increasing the risk of early-onset Alzheimer's disease (AD). The endocannabinoid system may serve as a therapeutic target for cognitive deficits by inhibiting cannabinoid type-1 receptor (CB1R) function. METHODS: CB1R expression was analyzed in the hippocampi of aged DS-associated AD (DSAD) individuals and middle-aged Ts65Dn mice. Long-term oral treatment with the CB1R antagonist rimonabant was used to assess its effects on memory and neuroinflammation in the Ts65Dn mouse model of DS. RESULTS: CB1R expression was significantly increased in both aged DSAD subjects (specifically in the dentate gyrus and CA2 posterior hippocampal subregions) and Ts65Dn mice. Long-term rimonabant treatment improved memory performance, normalized microglial morphology, and reduced plasma inflammatory markers in trisomic mice without preventing neuron decline. DISCUSSION: These findings suggest that sustained CB1R inhibition may enhance cognitive function by modulating neuroinflammation, highlighting its therapeutic potential for cognitive impairments in DS. Highlights: Cannabinoid type-1 receptor (CB1R) expression is increased in the posterior hippocampus of aged Down syndrome (DS) subjects and Ts65Dn mice. Long-term rimonabant treatment enhances memory in middle-aged Ts65Dn mice. CB1R inhibition shifts neuroinflammatory features in Ts65Dn mice. CB1R inhibition does not halt noradrenergic/cholinergic neurodegeneration in Ts65Dn. CB1R inhibition presents potential for memory improvement in DS-related deficits., Ministerio de Ciencia, Innovación y Universidades, Grant/Award Numbers:RTI2018-099282-B-I00, PID2021-123482OB-I00-/MICIN/AEI/10.13039/501100011033/FEDER,PID2020- 120029GB-I00/MICIN/AEI/10.13039/501100011033; Fondation Jérôme Lejeune, Grant/Award Numbers:1896_GRT-2019B, #2416_GRT-2024B; Bright Focus foundation, Grant/Award Number:CA2018010; Ministerio de Sanidad, Servicios Sociales e Igualdad, Grant/Award Number:RD16/0017/0020; Departament de Recerca i Universitats, Generalitat de Catalunya,Grant/Award Number: 2017SGR-669 Departament d'Economia i Coneixement, Generalitat de Catalunya, Grant/Award Number: 2017SGR-138; Institució Catalana de Recerca i Estudis Avançats, ICREA-Acadèmia2021
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Auricular transcutaneous vagus nerve stimulation acutely modulates brain connectivity in mice.

  • Brambilla Pisoni, Cecilia, 1993-
  • Muñoz-Moreno, Emma
  • Gallego-Amaro, Ianire
  • Maldonado, Rafael, 1961-
  • Ivorra Cano, Antoni, 1974-
  • Soria Rodríguez, Guadalupe
  • Ozaita Mintegui, Andrés, 1969-
Brain electrical stimulation techniques take advantage of the intrinsic plasticity of the nervous system, opening a wide range of therapeutic applications. Vagus nerve stimulation (VNS) is an approved adjuvant for drug-resistant epilepsy and depression. Its non-invasive form, auricular transcutaneous VNS (atVNS), is under investigation for applications, including cognitive improvement. We aimed to study the effects of atVNS on brain connectivity, under conditions that improved memory persistence in CD-1 male mice. Acute atVNS in the cymba conchae of the left ear was performed using a standard stimulation protocol under light isoflurane anesthesia, immediately or 3 h after the training/familiarization phase of the novel object-recognition memory test (NORT). Another cohort of mice was used for bilateral c-Fos analysis after atVNS administration. Spearman correlation of c-Fos density between each pair of the thirty brain regions analyzed allowed obtaining the network of significant functional connections in stimulated and non-stimulated control brains. NORT performance was enhanced when atVNS was delivered just after, but not 3 h after, the familiarization phase of the task. No alterations in c-Fos density were associated with electrostimulation, but a significant effect of atVNS was observed on c-Fos-based functional connectivity. atVNS induced a clear reorganization of the network, increasing the inter-hemisphere connections and the connectivity of locus coeruleus. Our results provide new insights into the effects of atVNS on memory performance and brain connectivity extending our knowledge of the biological mechanisms of bioelectronics in medicine., The project that gave rise to these results received the support of a fellowship from la Caixa Foundation (ID 100010434). The fellowship code is LCF/BQ/IN18/11660012 (CB-P). This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Slodowska-Curie grant agreement No. 713673. This work was supported by the Ministerio de Economía, Innovación y Competitividad (MINECO) (#RTI2018-099282-B-I00 to AO and PID2020-120029GB-I00/MICIN/AEI/10.13039/501100011033 to RM); the Instituto de Salud Carlos III (#RD16/0017/0020 to RM and PI18/00893 cofunded by ERDF A way to make Europe to GS); the Generalitat de Catalunya (2017SGR-669 to RM); the ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to AO, AI, and RM; Grant Unidad de Excelencia María de Maeztu, funded by the MINECO (#MDM-2014-0370); and PLAN E (Plan Español para el Estímulo de la Economía y el Empleo). FEDER funding is also acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional protection in J20/VLW mice: A model of non-demented with Alzheimer's disease neuropathology

  • Dávila-Bouziguet, Eva
  • Casòliba-Melich, Arnau
  • Targa-Fabra, Georgina
  • Galera-López, Lorena
  • Ozaita, Andrés
  • Maldonado, Rafael
  • Ávila, Jesús
  • Delgado-García, Jose M
  • Gruart, Agnès
  • Soriano, Eduardo
  • Pascual, Marta
Alzheimer's disease comprises amyloid-β and hyperphosphorylated Tau accumulation, imbalanced neuronal activity, aberrant oscillatory rhythms and cognitive deficits. Non-demented with Alzheimer's disease neuropathology defines a novel clinical entity with amyloid-β and Tau pathologies but preserved cognition. The mechanisms underlying such neuroprotection remain undetermined and animal models of non-demented with Alzheimer's disease neuropathology are currently unavailable. We demonstrate that J20/VLW mice (accumulating amyloid-β and hyperphosphorylated Tau) exhibit preserved hippocampal rhythmic activity and cognition, as opposed to J20 and VLW animals, which show significant alterations. Furthermore, we show that the overexpression of mutant human Tau in coexistence with amyloid-β accumulation renders a particular hyperphosphorylated Tau signature in hippocampal interneurons. The GABAergic septohippocampal pathway, responsible for hippocampal rhythmic activity, is preserved in J20/VLW mice, in contrast to single mutants. Our data highlight J20/VLW mice as a suitable animal model in which to explore the mechanisms driving cognitive preservation in non-demented with Alzheimer's disease neuropathology. Moreover, they suggest that a differential Tau phosphorylation pattern in hippocampal interneurons prevents the loss of GABAergic septohippocampal innervation and alterations in local field potentials, thereby avoiding cognitive deficits., This work was supported by funds from the Ministry of Economy and Competitiveness (SAF2016-76340-R) and the Ministry of Science, Innovation and Universities (PID2019-106764RB-C21/AEI/ 10.13039/501100011033) to E.S. and (RTI2018-099282-B-I00) to A.O., from the Ministry of Economy, Industry and Competitiveness (BFU2017-82375-R) to A.G. and J.M.D.-G; by the Marıa de Maeztu Unit of Excellence awarded to the Institute of Neurosciences of the University of Barcelona (MDM-2017–0729, Ministry of Science, Innovation and Universities); by an FPU grant from the Ministry of Education, Culture and Sport (FPU2016-07395) awarded to E.D.-B., and by an FPI grant from the Ministry of Economy, Industry and Competitiveness (BES-2016–077950) awarded to L.G.-L.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome

  • Navarro Romero, Alba, 1990-
  • Galera López, Lorena, 1993-
  • Ortiz Romero, Paula, 1994-
  • Llorente-Ovejero, Alberto
  • Los Reyes-Ramírez, Lucía de
  • Bengoetxea de Tena, Iker
  • Garcia-Elias Heras, Anna
  • Mas Stachurska, Aleksandra
  • Reixachs i Solé, Marina
  • Pastor, Antonio
  • Torre Fornell, Rafael de la
  • Maldonado, Rafael, 1961-
  • Benito Villabriga, Begoña
  • Eyras Jiménez, Eduardo
  • Rodríguez-Puertas, Rafael
  • Campuzano Uceda, María Victoria
  • Ozaita Mintegui, Andrés, 1969-
Williams-Beuren syndrome (WBS) is a rare genetic multisystemic disorder characterized by mild-to-moderate intellectual disability and hypersocial phenotype, while the most life-threatening features are cardiovascular abnormalities. Nowadays, there are no pharmacological treatments to directly ameliorate the main traits of WBS. The endocannabinoid system (ECS), given its relevance for both cognitive and cardiovascular function, could be a potential druggable target in this syndrome. We analyzed the components of the ECS in the complete deletion (CD) mouse model of WBS and assessed the impact of its pharmacological modulation in key phenotypes relevant for WBS. CD mice showed the characteristic hypersociable phenotype with no preference for social novelty and poor short-term object-recognition performance. Brain cannabinoid type-1 receptor (CB1R) in CD male mice showed alterations in density and coupling with no detectable change in main endocannabinoids. Endocannabinoid signaling modulation with subchronic (10 days) JZL184, a selective inhibitor of monoacylglycerol lipase, specifically normalized the social and cognitive phenotype of CD mice. Notably, JZL184 treatment improved cardiovascular function and restored gene expression patterns in cardiac tissue. These results reveal the modulation of the ECS as a promising novel therapeutic approach to improve key phenotypic alterations in WBS., This study was supported by Ministerio de Economía, Innovación y Competitividad (MINECO), Spain #RTI2018-099282-B-I00B to A.O., #SAF2017-84060-R to R.M.; Generalitat de Catalunya, Spain (2017SGR-669 to R.M.); Ministerio de Ciencia e Innovación (SAF2016-78508-R; AEI/MINEICO/FEDER, UE) to VC. Basque Government IT1454-22 to the 'Neurochemistry and Neurodegeneration' consolidated research group to R R-P. Instituto de Salud Carlos III (PI20/00153, co-funded by the European Union [ERDF 'A way to make Europe']) to R R-P. ICREA (Institució Catalana de Recerca i Estudis Avançats, Spain) Academia to A.O. and R.M. Grant 'Unidad de Excelencia María de Maeztu', funded by the MINECO (#MDM-2014-0370); IPEP MdM 2017 to A.O. and E.E. FEDER, European Commission funding is also acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Auricular transcutaneous vagus nerve stimulation acutely modulates brain connectivity in mice.

  • Brambilla Pisoni, Cecilia, 1993-
  • Muñoz Moreno, Emma
  • Gallego-Amaro, Ianire
  • Maldonado, Rafael, 1961-
  • Ivorra Cano, Antoni, 1974-
  • Soria Rodríguez, Guadalupe
  • Ozaita Mintegui, Andrés, 1969-
Brain electrical stimulation techniques take advantage of the intrinsic plasticity of the nervous system, opening a wide range of therapeutic applications. Vagus nerve stimulation (VNS) is an approved adjuvant for drug-resistant epilepsy and depression. Its non-invasive form, auricular transcutaneous VNS (atVNS), is under investigation for applications, including cognitive improvement. We aimed to study the effects of atVNS on brain connectivity, under conditions that improved memory persistence in CD-1 male mice. Acute atVNS in the cymba conchae of the left ear was performed using a standard stimulation protocol under light isoflurane anesthesia, immediately or 3 h after the training/familiarization phase of the novel object-recognition memory test (NORT). Another cohort of mice was used for bilateral c-Fos analysis after atVNS administration. Spearman correlation of c-Fos density between each pair of the thirty brain regions analyzed allowed obtaining the network of significant functional connections in stimulated and non-stimulated control brains. NORT performance was enhanced when atVNS was delivered just after, but not 3 h after, the familiarization phase of the task. No alterations in c-Fos density were associated with electrostimulation, but a significant effect of atVNS was observed on c-Fos-based functional connectivity. atVNS induced a clear reorganization of the network, increasing the inter-hemisphere connections and the connectivity of locus coeruleus. Our results provide new insights into the effects of atVNS on memory performance and brain connectivity extending our knowledge of the biological mechanisms of bioelectronics in medicine., The project that gave rise to these results received the support of a fellowship from la Caixa Foundation (ID 100010434). The fellowship code is LCF/BQ/IN18/11660012 (CB-P). This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Slodowska-Curie grant agreement No. 713673. This work was supported by the Ministerio de Economía, Innovación y Competitividad (MINECO) (#RTI2018-099282-B-I00 to AO and PID2020-120029GB-I00/MICIN/AEI/10.13039/501100011033 to RM); the Instituto de Salud Carlos III (#RD16/0017/0020 to RM and PI18/00893 cofunded by ERDF A way to make Europe to GS); the Generalitat de Catalunya (2017SGR-669 to RM); the ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to AO, AI, and RM; Grant Unidad de Excelencia María de Maeztu, funded by the MINECO (#MDM-2014-0370); and PLAN E (Plan Español para el Estímulo de la Economía y el Empleo). FEDER funding is also acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting dysregulated CB1 receptors in a down syndrome mouse model improves neurological outcomes

  • Vázquez-Oliver, Anna
  • Pérez-García, Silvia
  • Romero-Pérez, Rafael
  • Pizarro Lozano, Ma. Nieves
  • Galarraga-Shinin, Diana
  • Molina-Porcel, Laura
  • Torre Fornell, Rafael de la
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
INTRODUCTION: Down syndrome (DS) is the most common genetic cause of intellectual disability, affecting cognitive function and increasing the risk of early-onset Alzheimer's disease (AD). The endocannabinoid system may serve as a therapeutic target for cognitive deficits by inhibiting cannabinoid type-1 receptor (CB1R) function. METHODS: CB1R expression was analyzed in the hippocampi of aged DS-associated AD (DSAD) individuals and middle-aged Ts65Dn mice. Long-term oral treatment with the CB1R antagonist rimonabant was used to assess its effects on memory and neuroinflammation in the Ts65Dn mouse model of DS. RESULTS: CB1R expression was significantly increased in both aged DSAD subjects (specifically in the dentate gyrus and CA2 posterior hippocampal subregions) and Ts65Dn mice. Long-term rimonabant treatment improved memory performance, normalized microglial morphology, and reduced plasma inflammatory markers in trisomic mice without preventing neuron decline. DISCUSSION: These findings suggest that sustained CB1R inhibition may enhance cognitive function by modulating neuroinflammation, highlighting its therapeutic potential for cognitive impairments in DS. Highlights: Cannabinoid type-1 receptor (CB1R) expression is increased in the posterior hippocampus of aged Down syndrome (DS) subjects and Ts65Dn mice. Long-term rimonabant treatment enhances memory in middle-aged Ts65Dn mice. CB1R inhibition shifts neuroinflammatory features in Ts65Dn mice. CB1R inhibition does not halt noradrenergic/cholinergic neurodegeneration in Ts65Dn. CB1R inhibition presents potential for memory improvement in DS-related deficits., Ministerio de Ciencia, Innovación y Universidades, Grant/Award Numbers:RTI2018-099282-B-I00, PID2021-123482OB-I00-/MICIN/AEI/10.13039/501100011033/FEDER,PID2020- 120029GB-I00/MICIN/AEI/10.13039/501100011033; Fondation Jérôme Lejeune, Grant/Award Numbers:1896_GRT-2019B, #2416_GRT-2024B; Bright Focus foundation, Grant/Award Number:CA2018010; Ministerio de Sanidad, Servicios Sociales e Igualdad, Grant/Award Number:RD16/0017/0020; Departament de Recerca i Universitats, Generalitat de Catalunya,Grant/Award Number: 2017SGR-669 Departament d'Economia i Coneixement, Generalitat de Catalunya, Grant/Award Number: 2017SGR-138; Institució Catalana de Recerca i Estudis Avançats, ICREA-Acadèmia2021
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome

  • Navarro-Romero, Alba
  • Galera-López, Lorena
  • Ortiz-Romero, Paula|||0000-0002-6378-6763
  • Llorente-Ovejero, Alberto
  • de los Reyes-Ramírez, Lucía
  • Bengoetxea de Tena, Iker
  • Garcia-Elias, Anna|||0000-0002-6609-6119
  • Mas-Stachurska, Aleksandra|||0000-0003-4947-4111
  • Reixachs-Solé, Marina
  • Pastor, Antoni|||0000-0003-3692-0696
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Maldonado, Rafael|||0000-0002-4359-8773
  • Benito Villabriga, Begoña|||0000-0002-8668-1251
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Rodríguez-Puertas, Rafael|||0000-0003-4517-5114
  • Campuzano, Victoria|||0000-0001-8128-2641
  • Ozaita, Andres|||0000-0002-2239-7403
Williams-Beuren syndrome (WBS) is a rare genetic multisystemic disorder characterized by mild-to-moderate intellectual disability and hypersocial phenotype, while the most life-threatening features are cardiovascular abnormalities. Nowadays, there are no pharmacological treatments to directly ameliorate the main traits of WBS. The endocannabinoid system (ECS), given its relevance for both cognitive and cardiovascular function, could be a potential druggable target in this syndrome. We analyzed the components of the ECS in the complete deletion (CD) mouse model of WBS and assessed the impact of its pharmacological modulation in key phenotypes relevant for WBS. CD mice showed the characteristic hypersociable phenotype with no preference for social novelty and poor short-term object-recognition performance. Brain cannabinoid type-1 receptor (CB1R) in CD male mice showed alterations in density and coupling with no detectable change in main endocannabinoids. Endocannabinoid signaling modulation with subchronic (10 days) JZL184, a selective inhibitor of monoacylglycerol lipase, specifically normalized the social and cognitive phenotype of CD mice. Notably, JZL184 treatment improved cardiovascular function and restored gene expression patterns in cardiac tissue. These results reveal the modulation of the ECS as a promising novel therapeutic approach to improve key phenotypic alterations in WBS. Williams-Beuren syndrome (WBS) is a rare disorder that causes hyper-social behavior, intellectual disability, memory problems, and life-threatening overgrowth of the heart. Behavioral therapies can help improve the cognitive and social aspects of the syndrome and surgery is sometimes used to treat the effects on the heart, although often with limited success. However, there are currently no medications available to treat WBS. The endocannabinoid system - which consists of cannabis-like chemical messengers that bind to specific cannabinoid receptor proteins - has been shown to influence cognitive and social behaviors, as well as certain functions of the heart. This has led scientists to suspect that the endocannabinoid system may play a role in WBS, and drugs modifying this network of chemical messengers could help treat the rare condition. To investigate, Navarro-Romero, Galera-López et al. studied mice which had the same genetic deletion found in patients with WBS. Similar to humans, the male mice displayed hyper-social behaviors, had memory deficits and enlarged hearts. Navarro-Romero, Galera-López et al. found that these mutant mice also had differences in the function of the receptor protein cannabinoid type-1 (CB1). The genetically modified mice were then treated with an experimental drug called JZL184 that blocks the breakdown of endocannabinoids which bind to the CB1 receptor. This normalized the number and function of receptors in the brains of the WBS mice, and reduced their social and memory symptoms. The treatment also restored the animals' heart cells to a more normal size, improved the function of their heart tissue, and led to lower blood pressure. Further experiments revealed that the drug caused the mutant mice to activate many genes in their heart muscle cells to the same level as normal, healthy mice. These findings suggest that JZL184 or other drugs targeting the endocannabinoid system may help ease the symptoms associated with WBS. More studies are needed to test the drug's effectiveness in humans with this syndrome. Furthermore, the dramatic effect JZL184 has on the heart suggests that it might also help treat high blood pressure or conditions that cause the overgrowth of heart cells.